SynthesisJournal of gastrointestinal cancer2025
Improving Colorectal Cancer Detection with AI-Assisted Colonoscopy: A Systematic Review and Meta-Analysis of 38 RCTs with GRADE Assessment.
Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemorrhoids and Rectal Cancer: A Systematic Review of Clinical Overlap, Diagnostic Misclassification, and Early Detection Strategies for Primary Care.Journal of multidisciplinary healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Early detection of precancerous lesions such as adenomas and polyps is vital for prevention, yet standard colonoscopy may miss up to 26% of adenomas. Artificial intelligence (AI)-assisted colonoscopy has emerged as a promising tool to enhance lesion detection. This meta-analysis provides an updated synthesis of randomized controlled trials (RCTs) evaluating the diagnostic performance of AI-assisted versus standard colonoscopy.
methodsFollowing PRISMA guidelines, a comprehensive search of PubMed, Cochrane, Web of Science, and Scopus identified 38 RCTs including 29,745 participants. Pooled risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by geographical region and AI manufacturer were performed to explore heterogeneity. Certainty of evidence was rated using the GRADE approach, and publication bias was assessed through funnel plots and Egger's test.
resultsAI-assisted colonoscopy significantly improved adenoma detection rate (ADR: RR = 1.19, 95% CI 1.14-1.25) and polyp detection rate (PDR: RR = 1.19, 95% CI 1.13-1.25), while reducing adenoma miss rate (AMR: RR = 0.52, 95% CI 0.38-0.72) and polyp miss rate (PMR: RR = 0.53, 95% CI 0.33-0.88). The mean number of adenomas per colonoscopy increased (MD = 0.20, 95% CI 0.14-0.25). AI modestly prolonged withdrawal time (MD = 0.46 min, 95% CI 0.26-0.66). No significant difference was observed for carcinoma detection (RR = 1.12) or advanced adenoma miss rate (RR = 0.67). Sessile serrated lesion detection showed a nonsignificant trend toward improvement (RR = 1.13), becoming significant after outlier exclusion (RR = 1.23). Subgroup analyses revealed higher ADR improvement in East Asian studies and with specific AI systems (e.g., Wision AI). Egger's test suggested minor small-study effects for ADR and withdrawal time.
conclusionsAI-assisted colonoscopy substantially enhances adenoma and polyp detection while reducing miss rates. However, its benefit for carcinoma and sessile serrated lesion detection remains uncertain. Further standardized RCTs with long-term follow-up are warranted to confirm its role in colorectal cancer screening.
Indexed as
Identifiers
41417282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.